Cue Biopharma, Inc. Logo

Cue Biopharma, Inc.

Develops injectable biologics to selectively activate T cells for oncology & autoimmune disease.

CUE | US

Overview

Corporate Details

ISIN(s):
US22978P1066
LEI:
Country:
United States of America
Address:
40 GUEST STREET, 2135 BOSTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company that develops a novel class of injectable biologics to selectively engage and modulate disease-specific T cells. The company's proprietary Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform engineers therapeutics designed to mimic natural immune signals. This approach aims to selectively expand and activate specific immune cells directly within the patient's body, mobilizing the immune system to treat serious diseases. Cue Biopharma's pipeline focuses on developing precision immunotherapies for oncology and autoimmune and inflammatory diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cue Biopharma, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cue Biopharma, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cue Biopharma, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
PRECISION BIOSCIENCES INC Logo
A clinical-stage company using ARCUS gene editing to treat cancer and rare genetic diseases.
United States of America DTIL
Develops sensitive point-of-care biomarker diagnostics for human and animal health.
South Korea 335810
Prelude Therapeutics Inc Logo
Clinical-stage oncology company developing novel protein degraders and ADCs for cancer.
United States of America PRLD
A global CDEMO offering end-to-end solutions for antibody therapeutics and biologics.
South Korea 334970
Develops affordable biosimilars and novel antibody drugs for life-threatening diseases.
Singapore 950210
Prestige Consumer Healthcare Inc. Logo
Develops and markets leading over-the-counter brands for personal healthcare and wellness.
United States of America PBH
Processa Pharmaceuticals, Inc. Logo
Develops next-gen chemo and therapies for chronic and life-threatening diseases.
United States of America PCSA
Develops protein-based immunotherapies for metabolic diseases, immune disorders, and cancer.
South Korea 296160
PROKIDNEY CORP. Logo
Develops cellular therapies to preserve kidney function for patients with advanced Chronic Kidney Disease.
United States of America PROK
ProMIS Neurosciences Inc. Logo
Developing selective antibody therapies targeting toxic proteins in neurodegenerative diseases.
United States of America PMN

Talk to a Data Expert

Have a question? We'll get back to you promptly.